LFG
ZBIO

Larson Financial Group’s Zenas BioPharma ZBIO Stock Holding History

Larson Financial Group’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.5K Buy
454
+161
+55% +$3.2K ﹤0.01% 2317
2026
Q1 		$5.73K Buy
293
+274
+1,442% +$6.15K ﹤0.01% 2534
2025
Q4 		$690 Buy
+19
New +$625 ﹤0.01% 3042

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $242M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Larson Financial Group's ZBIO Position: Q2 2026 in Review

Larson Financial Group increased its Zenas BioPharma (ZBIO) stake by 55% in Q2 2026, buying an estimated $3.2K and bringing the position to 454 shares worth $11.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2317.

Larson Financial Group first reported a position in ZBIO in Q4 2025 and has held it in 3 quarters since. 144 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

  • Larson Financial Group held 454 shares of Zenas BioPharma worth $11.5K as of Q2 2026.
  • Larson Financial Group bought 161 Zenas BioPharma shares in Q2 2026, an estimated $3.2K.
  • Zenas BioPharma made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #2317 holding.
  • Larson Financial Group first reported a position in Zenas BioPharma in Q4 2025 and has held it in 3 quarters since.
  • 144 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.